Drug Target Review

APRIL 9, 2024

In a previous study, we showed that these peptides decorate all cellular RNAs and thus impair the binding of RNA-binding proteins to RNA. Initial works from the lab concentrated on exploring the role of replicative stress in cancer and ageing, for which the group combined cell biology, mouse models and drug development projects.

RNA 64

RNA Cell Biology Clinical Development DNA 64

Drug Target Review

AUGUST 24, 2023

Neutralising GDF-15 with CatalYm’s anti-GDF-15 antibody visugromab was shown to reverse its inhibitory effects and to re-sensitise tumours to anti-PD-1 treatment, achieving commensurate survival benefit of anti-GDF-15-anti-PD-1 combination therapy in vivo. Current Opinion in Cell Biology. in North America) in late 2017.

Treatment 98

Treatment Therapies Clinical Development Cell Biology 98

Codon

APRIL 9, 2023

“Computer science is to biology what calculus is to physics.” ” — Harold Morowitz 🔥 Ten Amazing Things (that happened this week…) A CAR-T therapy was tested in 27 children with neuroblastomas. The CAR-T cells were detectable in 26 out of 27 children after 30 months. Nature Chemical Biology.

Therapies 52

Therapies RNA Engineering Vaccine 52

Broad Institute

OCTOBER 11, 2023

By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. The team found that deleting the gene Ptpn2 made tumors sensitive to PD-1 therapy, and they published their findings in Nature in 2017.

Research 137

Research Immune Response Clinical Trials Cell Biology 137

Drug Discovery World

DECEMBER 15, 2022

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies. Likewise, Lessard et al.

DNA 130

DNA Clinical Trials Therapies RNA 130

Codon

APRIL 30, 2023

5/ Lots O’ Gene Therapies Not one, but two applications for sickle-cell gene therapies have been submitted to the F.D.A. If approved, these wouldn’t be the first gene therapies on the market, but they would be the first gene therapies for a disease that affects something like 100,000 Americans.

Vaccine 52

Vaccine Engineering DNA RNA 52

Codon

APRIL 30, 2023

5/ Lots O’ Gene Therapies Not one, but two applications for sickle-cell gene therapies have been submitted to the F.D.A. If approved, these wouldn’t be the first gene therapies on the market, but they would be the first gene therapies for a disease that affects something like 100,000 Americans.

Vaccine 52

Vaccine Engineering DNA RNA 52